Download PDF
1
/
Pages
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Perception of the impact of intravenous biological treatment on the work and professional environment in patients with inflammatory bowel disease
Carlos González-Muñoza; Cristina Gely; Jordi Gordillo; Margalida Calafat; Federico Bertoletti; Fiorella Cañete; Míriam Mañosa; Alberto López-Faba; Paola Torres; Eugeni Domènech; Esther Garcia-Planella;
Gastroenterol Hepatol. 2024;47:
Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study
Rodrigo Bremer Nones; Eron Fabio Miranda; Gustavo de Nardi Marçal; Fernanda da Silva Barbosa Baraúna; Marcela Rocha Loures; Paula Cenira Senger; Daniela Oliveira Magro; Paulo Gustavo Kotze;
Gastroenterol Hepatol. 2024;47:711-20
Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study
Lidia Serrano Díaz; Carles Iniesta Navalón; Rosa Gómez Espín; Isabel Nicolás De Prado; Enrique Bernal Morell; Lorena Rentero Redondo;
Gastroenterol Hepatol. 2024;47:553-61